glp1
Wegovy (semaglutide) tracker
Educational reference for Wegovy (semaglutide). Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
165 h
Tmax
24 h
Category
glp1
Wegovy is Novo Nordisk's brand of semaglutide marketed for chronic weight management.
Mechanism
Wegovy is a brand name for semaglutide, a GLP-1 receptor agonist, at doses used for weight management. See the semaglutide entry for the full mechanism.
Research summary
Wegovy is the semaglutide product approved for chronic weight management (STEP program). See the semaglutide entry for broader context.
Reported side effects
As a semaglutide product, gastrointestinal effects are most commonly reported; prescribing information includes class warnings. See the semaglutide entry. This is not a complete safety profile.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- Wegovy prescribing information / STEP program · FDA prescribing information (2021)available via DailyMed; see semaglutide entry
References
TrackPep er en app til registrering. Den registrerer det, du indtaster, og anbefaler eller beregner aldrig mængder.